Cuban Academy of Sciences develops vaccines for the treatment of non-small cell lung cancer- Vaxira and CIMAvax. This latest type of vaccine that can treat non-small cell lung cancer (NSCLC) has undergone phase 3 clinical validation and has a good effect on non-small cell lung cancer. It has now entered clinical applications in Kuba jeung Peru. Hasil tina panilitian anu narik ati ieu ngamungkinkeun tilas Présidén AS Barack Obama pikeun ngangkat larangan perdagangan 55 taun saatos nganjang Kuba, and introduced the latest anti-cancer technology to the United States in 2015. The US Food and Drug Administration (FDA) has approved the United States to conduct a clinical trial of a lung cancer vaccine developed in Cuba, which can stimulate the lung cancer patient’s own immune system.
Naon CIMAvax?
CIMAvax-EGF is a kanker paru treatment that was developed in Cuba. It is a type of immunotherapy that harnesses the body’s immune system to fight lung cancer. In 2017, Roswell Park initiated a clinical trial involving CIMAvax. Trial is a Phase I/II study of CIMAvax-EGF in combination with the anti-PD1 checkpoint inhibitor nivolumab (Opdivo®) in patients previously treated for advanced kanker paru sél non-leutik (NSCLC).
Kumaha jalan CIMAvax?
Developed by researchers at the Center for Molecular Immunology (CIM) in Havana, Cuba, CIMAvax-EGF blocks a type of protein — epidermal growth factor (EGF) — that cancer cells need to grow. It does not kill cells directly, cancerous cells or otherwise, but “starves” them by preventing EGF from attaching to its proper receptor (EGFR) on the cell. This connection is required for the cell to grow and proliferate. Without it, the cancer cell does not multiply, and dies. CIMAvax blocks EGF by manipulating the patient’s immune response.
"Protein pamawa" dina CIMAvax micu sistim imun pikeun ngahasilkeun antibodi ngalawan protéin EGF pikeun nétralisasi. Ieu ngaleyurkeun sirkulasi EGF tina getih, nyabut sél kanker konci penting ieu pikeun tumuh sareng salamet.
More than 5,000 lung cancer patients have been treated with this unique immunotherapy, and several international studies have indicated prolonged tumor stabilization and improved overall survival and quality of life for patients receiving CIMAvax. CIMAvax is an approved treatment for lung cancer in Argentina, Bosnia and Herzegovina, Colombia, Cuba, Kazakhstan, Paraguay and Peru.
Naon Vaxira?
Vaxira® is a therapeutic vaccine for the treatment of non-small cell lung cancer (NSCLC). It is composed of Racotumomab and aluminum hydroxide adjuvant.
Racotumomab mangrupikeun anti-idiotypic monoclonal antibody anu nyababkeun dina pasién réspon imunitas kuat ngalawan gangliosides glikololid khusus (NeuGcGM3) anu aya dina sél tumor. Vaxira® ningkatkeun salamet penderita NSCLC dina tahap anu berulang atanapi maju (IIIB / IV) dibandingkeun sareng perawatan anu pangrojongna. Vaxira® ditoleransi sareng profil kaamanan na tiasa ditampi. Kajadian parah paling umum dilokalisasi (dina tempat administrasi), hampang sareng samentawis.
Malah jalma pasién anu diimunisasi ku Vaxira® saatos panyakitna maju parantos nunjukkeun paningkatan dina salamet keseluruhan.
nyusun: Unggal vial tina VAXIRA® ngandung: mAb Racotumomab 1.00 mg, aluminium hidroksida [Al (OH) 3] 5.00 mg, tris (hidroksiametil) aminometana 12.14 mg, natrium klorida 3.40 mg, cai pikeun suntikan qs 1.0 ml. Vaxira® mangrupikeun agén imunoterapi diwangun ku anti-idiotypic monoclonal antibody Racotumomab sareng aluminium hidroksida (AH), mangrupikeun bantosan anu seueur dianggo. AH ningkatkeun produksi antibodi, tapi sanés imunogenik atanapi hapten. Éta kalakuanana salaku depot dina tempat suntikan anu antigenna dileupaskeun lalaunan sareng, dina waktos anu sasarengan, éta nyababkeun pembentukan granulomas anu narik sél imunokompeten sapertos sél plasma anu ngahasilkeun antibodi. AH tiasa langsung ngarangsang monosit pikeun ngahasilkeun sitokin proinflamasi anu tiasa ngaktipkeun sél T, sareng éta ogé tiasa ngarangsang réspon sél B.
Kumaha mésér CIMAvax sareng Vaxira di India?
CIMAvax and Vaxira at present are not available in India. These vaccines need to be ordered for personalized treatment. To order the medicine please WhatsApp patient details to + 91 96 1588 1588.
